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Treatment for localized malignant melanoma is difficult and the prognosis is
still uncertain in many cases. Although clinical parameters such as lymph
node involvement and thickness of the tumour are helpful, other diagnostic
tools are urgently needed to allow for optimal prediction of the clinical
course and choice of treatment. For this purpose efforts have been made to
detect micrometastases in blood (Brossart et al, 1995; Foss et al, 1995; Hoon
et al, 1995; Buzaid and Balch 1996; Mellado et al, 1996; Gläser et al, 1997;
Jung et al, 1997; Reinhold et al, 1997; Farthmann et al, 1998; Ghossein et al,
1998; Curry et al, 1998; De Vries et al, 1999; Palmieri et al, 1999) and in the
regional lymph nodes by immunohistochemistry or reverse transcriptase
polymerase chain reaction (RT-PCR) (Battyani et al, 1993; Wang et al,
1994; Rankin, 1996; Van der Velde-Zimmermann et al, 1996; Blaheta et al,
1998; Goydos et al, 1998; Hatta et al, 1998; Bieligk et al, 1999).
Among these techniques the nested RT-PCR is the most sensi-
tive method: in spike experiments the detection limit ranges from
1 to 10 tumour cells in 107 peripheral blood lymphocytes (PBLs)
(Hoon et al, 1995; Gläser et al, 1997; Jung et al, 1997; Farthmann
et al, 1998; Palmieri et al, 1999), whereas for immunohistochem-
istry the detection limit is 1 tumour cell in 105 normal cells (Hatta
et al, 1998).
The expression of the tyrosinase gene is most widely used for
the detection of circulating melanoma cells due to its high
percentage of expression in malignant melanoma.
In 1991, Smith et al reported that circulating melanoma cells
can be detected by amplification of tyrosinase mRNA. The initial
report led to a number of more detailed investigations regarding
the presence of tyrosinase RNA in peripheral blood of melanoma
patients (Brossart et al, 1995; Foss et al, 1995; Hoon et al, 1995;
Buzaid and Balch, 1996; Mellado et al, 1996; Gläser et al, 1997;
Jung et al, 1997; Reinhold et al, 1997; Curry et al, 1998;
Farthmann et al, 1998; Ghossein et al. 1998; Palmieri et al, 1999;
De Vries et al, 1999). The published tyrosinase mRNA RT-PCR
sensitivities in peripheral blood among stage III melanoma
patients range from 0% to 100%. Based on these results and their
own findings in 102 melanoma patients, Gläser et al (1997)
concluded that the detection of circulating tumour cells in
melanoma patients using the tyrosinase mRNA RT-PCR is not
sensitive enough for early detection.
Non-melanoma blood controls were, however, always negative
for expression of tyrosinase, using the nested RT-PCR; neverthe-
less, whether the same specificity can be reached for lymph nodes
is doubtful for two reasons. First, although evidently other tyrosi-
nase positive cells than melanoma cells, such as Schwann cells or
melanocytes, do not circulate, they could well be present in the
stroma of normal nodes. Secondly, studies of lymph nodes of
patients with stage I or II malignant melanoma (AJCC classifica-
tion), thus with clinically negative nodes, showed results that do
not seem to correspond with the clinical outcome. For instance
Wang et al (1994) found in 66% of 29 regional lymph node
samples tyrosinase positivity by RT-PCR, in melanoma patients
with a stage I or II melanoma. Therefore, the specificity of the
tyrosinase mRNA as a tumour marker in lymph nodes should be
further evaluated.
In the present study we tried to evaluate both sensitivity and
specificity for the detection of tyrosinase mRNA by means of
nested RT-PCR, both in blood and in lymph nodes.
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MATERIALS AND METHODS
Patients
For the use of human material informed consent and medical
ethical approval was obtained according to local hospital rules.
Blood was taken from six healthy donors and four patients with
a malignancy other than melanoma, of which one patient with
breast cancer was treated with gramulocyte colony-stimulating
factor (G-CSF).
Nine lymph nodes of patients without malignant melanoma
were analysed; by conventional haematoxylin and eosin (H&E)
staining in combination with immunohistochemistry only reac-
tivity was found in these lymph nodes. Among these patients,
three did have malignancy: one patient had a leiomyosarcoma
grade II of the uterus, one patient a non-seminoma testis stage I,
and one a cholangiocarcinoma. In the other six patients no malig-
nancy was found. Among these patients, two received immuno-
suppressive therapy, following a renal and a liver transplantation;
in the other four only a reactive lymph node was found.
Surgical specimens
Lymph nodes were obtained by standard surgical procedures. All
tissues were collected and dissected under stringent sterile condi-
tions to prevent RNA contamination. In the processing of the
samples special care was taken to prevent contact with skin in
order to avoid contamination with skin melanocytes.
Each lymph node was bisected: 4-mm frozen sections were
obtained from each half of the lymph node. These were immedi-
ately stored at –80°C until use for the nested RT-PCR. The
remaining tissue was formalin-fixed and paraffin-embedded and,
using standard procedures, examined both by conventional H&E
staining and by immunohistochemistry with S-100, HMB45 and
MAT-1 antibodies. By the latter analysis no tumour cells could be
detected.
Cell lines
The melanoma cell line SK23-mel was a gift of P Schrier
(University Hospital of Leiden, The Netherlands). Non-melanoma
cell lines used were: A2780, ovarian cancer (Rogan et al, 1984),
GLC16, lung cancer (Berendsen et al, 1988), NT2/D1, testis
cancer (Andrews et al, 1984), SW948, colon cancer (Leibovitz et
al, 1976). All the cell lines were grown under standard cell culture
conditions.
Primers
All primers were synthesized by Eurogentech (Searing, Belgium).
The sequences are:
HTYR1=TTGGCAGATTGTCTGTAGCC (outer, sense)
HTYR2=AGGCATTGTGCATGCTGCTT (outer, anti-sense)
HTYR3=GTCTTTATGCAATGGAACGC (nested, sense)
HTYR4=GCTATCCCAGTAAGTGGACT (nested, anti-sense)
b-actin sense=ACCACACCTTCTACAATGAGCTGCGTG
b-actin anti-sense=CACAGCTTCTCCTTAATGTCACGCACG.
Antibodies
The anti-tyrosinase antibody MAT-1 was purchased from
Brunschwig Chemie BV (Amsterdam, The Netherlands). The
antibody S-100 was purchased from Dako (Glostrup,
Denmark).
Reagents
All enzymes and reagents used in this study were purchased
from Gibco-BRL (Breda, The Netherlands).
Immunhistochemistry
Briefly, acetone fixed slides were stained by a standard two-step
immunoperoxidase staining protocol; the second step was
performed using a rabbit anti-mouse horseradish peroxidase-
labelled antibody (Dako, Glostrup, Denmark).
PBL isolation
For peripheral blood samples, the first vacuum tube of blood
drawn after venipuncture was discarded. For each sample, 16 ml
of peripheral venous blood were collected in EDTA containing
tubes. The blood was stored at 4°C and processed within 2–4 h.
Erythrocytes were lysed by incubating the samples with 30–40 ml
erythrocyte lysis buffer (155 mM ammonium chloride, 10 mM
potassium hydrogen carbonate, 0.1 mM potassium EDTA) in ice
for 10 min twice. After centrifugation pellets were washed twice
in phosphate-buffered saline solution (PBS) and stored at –20°C in
RNA extraction buffer GIT (4 M guanidiumthiocynate, 2%
b-mercaptoethanol).
RNA isolation
For all samples the total RNA was extracted with a kit (Qiagen,
Westburg BV, Leusden, The Netherlands), according to the manu-
facturer’s prescriptions. The amount and integrity of the extracted
RNA was evaluated by agarose gel electrophoresis.
c-DNA synthesis
Single-stranded c-DNA synthesis was carried out on 1 mg total
RNA with 25 pmole of each anti-sense b-actin and the tyrosinase-
specific HTYR2 primers together, according to the manufacturer’s
instructions. To prevent contamination, c-DNA synthesis, PCR
mix preparation and agarose electrophoresis were performed in
separate rooms.
Nested RT-PCR
For the first PCR reaction 1/10 of the c-DNA synthesis mix was
used. The reaction was carried out in 25 ml with 100 pmole of
tyrosinase primers (HTYR1, HTYR2) and b-actin primers
together, 1.5 mM megnesium chloride and 200 mM of each dNTP.
The reaction was carried out for 30 cycles, each cycle consisting
of: 1 min 95°C; 1 min 55°C; 1 min 72°C. Then 10 ml of each
sample were loaded on a 2% agarose gel. The presence of the
correct b-actin band (365 bp) indicates both the quality of the
RNA and the success of the first PCR reaction. The nested PCR
was performed using as a template a 1 to 100 dilution of the
product of the first PCR, with the same mix and cycle condition as
for the first PCR, but using primers HTYR3 and HTYR4. The
reaction were performed in a DNA thermal cycler (Perkin-Elmer,
Applied Biosystems, Nieuwekerk a/d IJssel, The Netherlands).Spike experiment
An homogenous suspension of SK23-mel cells was serially diluted
to a concentration ranging from 1 to 104 cells 100 ml–1 PBS.
Subsequently each cells suspension was added to 10 ml of blood
and the mixture was normally processed for PBLs isolation, c-
DNA synthesis and nested RT-PCR, as described above.
RESULTS
Lymph nodes
Tyrosinase was detected by nested RT-PCR in 6/9 lymph nodes of
non-melanoma patients (Table 1, Figure 1). By immunohisto-
chemistry none of the LNs showed aberrant cells with S-100
expression apart from the normal expression in interdigitating
cells, for either expression of tyrosinase using the MAT-1 antibody
could not be detected.
Cell lines
Tyrosinase was found to be positive by nested RT-PCR in 2/4 of
the tested cell lines: colon cell line SW948 and ovarian cell line
A2780; on the other hand none of the cell line tested was positive
for immunocytochemistry, with the anti-tyrosinase antibody 
MAT-1.
Blood samples
All non-melanoma patients, including the patient with breast
cancer treated with G-CSF (n = 4) and all healthy donors (n = 6)
were negative for the nested RT-PCR on tyrosinase in the blood,
suggesting a reasonable degree of specificity (0/10) for this assay
in blood. The blood sample of the patient treated with G-CSF
permitted the analysis of any effect of young leukocytes on the
specificity of the assay.
Spike experiment
To determine the sensitivity of the nested RT-PCR assay we
performed a spike experiment as described in Materials and
Methods. The results indicated a detection limit of 10 SK23-mel
cells in 107 PBLs.
DISCUSSION
The aim of this study was to determine specificity and sensitivity
of the nested RT-PCR on tyrosinase for the detection of
micrometastases in lymph nodes of malignant melanoma patients.
We first checked a number of lymph node biopsies of non-
melanoma patients. We found 6/9 positive samples. Contamination
of skin cells during the sample processing can not be excluded
completely, although this was done under very stringent
conditions.
These results are conflicting with the recent study by Blaheta
et al (1998) who found no positive results in lymph nodes of 40
non-melanoma patients. However, it is to be noted that in this
study, together with the nested RT-PCR an immunohistochemical
assay, is performed and eventual positive results are judged to be
positive only when confirmed by the detection of tyrosinase-
positive cells by means of immunohistochemistry. Thus, specificity
in this study is determined by immunohistology, which is ten times
less sensitive than nested RT-PCR.
On the other hand, considering the specificity of the nested
RT-PCR, our finding of positive results in lymph nodes of non-
melanoma patients is in agreement with the publications of Bieligk
et al (1998) and of Battyani et al (1993), who found tyrosinase
transcripts in a variety of normal organs, including lymph nodes,
but not in blood.
These results may be due to the presence of other tyrosinase-
positive cells than melanoma cells, like Schwann cells or
melanocytes. The presence of Schwann cells or melanocytes in
LNs is a commonly described phenomenon, and it has been
reported to range from 7.3% to 22% (Bautista et al, 1994).
A second cause for tyrosinase expression in lymph nodes could
be the phenomenon called ‘illegitimate transcription’ (Chelly et al,
1989), by which, due to a ‘leaky’ transcription regulation, some
‘luxury’ genes are expressed also in ‘contexts’ where they are
supposed to be off.
This phenomenon is probably the explanation for the positive
PCR results we found in 2/4 non-melanoma cell lines.
In conclusion, the nested RT-PCR on tyrosinase to detect the pres-
ence of malignant melanoma micrometastases in lymph nodes has
limited diagnostic value, due to the high percentage of false-positive
results in lymph nodes of non-melanoma patients.
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Figure 1 A 2% agarose gel with the product of the nested RT-PCR on
lymph nodes, as a 207 bp band. For diagnosis of patient no. see Table 1.
Slots: 1. Positive control: melanoma tissue; 2. Negative control: blood from a
healthy donor; 3. Negative control: blood from a healthy donor; 4. Negative
control: no template; 5. Patient no. 1; 6. Negative control: no template; 7.
Patient no. 2; 8. Patient no. 3; 9. Marker: 1114 bp, 900 bp, 692 bp, 501–
489 bp, 404 bp, 320 bp, 242 bp, 190 bp, 147 bp, 124 bp, 110 bp, 67 bp,
37–34–26–19 bp; 10. Patient no. 4; 11. Patient no. 5; 12. Patient no. 6; 13.
Patient no. 7; 14. Patient no. 8; 15. Patient no. 9.
Table 1 Results obtained on non-melanoma patients’ lymph nodes, with the
nested RT-PCR assay
Patients’ diagnosisa Results with nested RT-PCR
no-malignancy (n = 4); 50% positive
Patient nos 1, 2, 3, 4
Leiomyosarcoma (n = 1); Positive
Patient no. 5
Non-seminoma testis (n = 1); Negative
Patient no. 6
Cholangiocarcinoma (n = 1); Positive
Patient no. 7
Liver transplanstation (n = 1); Positive
Patient no. 8
Renal transplanstation (n = 1); Positive
Patient no. 9
aFor agarose gel and no. see Figure 1.Detection of tyrosinase mRNA in lymph nodes 187
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